Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.

Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

Published on by Oncology

Prof. Dr. Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

The First Medical Center, Chinese PLA General Hospital | China

AUTHOR PROFILE

ORCID ID

🌟YUNSHENG YANG, M.D. – A LEADER IN GASTROENTEROLOGY 🏥

🎓EARLY ACADEMIC PURSUITS 

Dr. Yunsheng Yang earned his M.D. from the First Military Medical University in 1995, laying the foundation for his illustrious medical career. He pursued postdoctoral training at the Fourth Military Medical University in China, further honing his expertise in gastroenterology. His academic journey extended internationally with visiting scholar positions at the University of Sydney’s Westmead Hospital in 2008 and Mayo Clinic Rochester in 2014, where he gained invaluable global exposure to advanced medical practices.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently, Dr. Yang serves as the Academic Director of the Department of Gastroenterology and Hepatology at the First Medical Center, Chinese PLA General Hospital (PLAGH, 301 Hospital) in Beijing, China. His leadership extends beyond national borders, with visiting or adjunct professorships at Shenzhen University, Universitas Amoiensis, and the University of Michigan, USA.

His involvement in prestigious medical societies includes being the immediate past president of the Chinese Society of Gastroenterology and the Director of the APSDE Training Center in PLAGH since 2006. Dr. Yang actively engages with the World Gastroenterology Organization (WGO), serving as a scientific committee member and having previously contributed to the WGO Endoscopy Group and Nomination Committee.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

Dr. Yang’s clinical expertise primarily revolves around gastrointestinal (GI) disorders and therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP). His research is focused on robot-assisted endoscopy and GI microbiota, where he has pioneered multiple innovative procedures in China, including:

  • Endoscopic suturing for GERD (2001)
  • Double balloon enteroscopy (2003)
  • Peroral video cholangioscopy and laser lithotripsy (2004)
  • Confocal endomicroscopy (2006)
  • MUSE for GERD (2017)
  • Fecal Microbiota Transplantation (FMT) clinical trials for IBD, autism, and Tourette syndrome (since 2014)

Notably, he led the development of the YunSRobot, a robot-assisted GI endoscopy system, successfully performing gastroscopy on human volunteers in 2017 and completing remote gastroscopy in 2021. These groundbreaking achievements have been published and indexed in PubMed.

📚IMPACT AND INFLUENCE 

Dr. Yang’s influence in the field of gastroenterology is reflected in his extensive publication record. He has authored over 200 articles in Chinese journals and more than 150 papers in international SCI-indexed journals, including prestigious titles such as Gastroenterology, Hepatology, The American Journal of Gastroenterology (AJG), Gastrointestinal Endoscopy (GIE), Alimentary Pharmacology & Therapeutics (AP&T), and Gut.

As an editorial board member for Gut and AP&T, and associate editor for MMR and JDD, he continues to shape the direction of gastroenterology research and clinical practice worldwide.

🌟ACADEMIC CITES AND RECOGNITION 

Dr. Yang’s research contributions have been extensively cited by peers in the medical and scientific communities. His innovations in endoscopic procedures and gastrointestinal microbiota research have influenced treatment protocols and technological advancements in digestive health worldwide. His pioneering work on FMT for neurological conditions and robotic-assisted endoscopy is setting new standards in precision medicine.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Dr. Yang’s enduring legacy lies in his transformative impact on gastroenterology, blending cutting-edge technology with clinical expertise. His leadership in developing robotic-assisted endoscopy has the potential to revolutionize non-invasive diagnostics and treatment, paving the way for AI-integrated endoscopic procedures.

Looking ahead, Dr. Yang continues to push the boundaries of GI research, particularly in the integration of robotics, microbiota-based therapies, and novel endoscopic interventions. His mentorship of young gastroenterologists ensures a lasting impact on the field, fostering the next generation of leaders in digestive health research and clinical innovation.

🌍CONCLUSION 

Dr. Yunsheng Yang stands as a trailblazer in the field of gastroenterology, with his extensive contributions in clinical practice, research, and technological innovation. His groundbreaking advancements in robot-assisted endoscopy and GI microbiota research have set new benchmarks in the medical field. His dedication to patient care, scientific discovery, and mentorship ensures his influence will resonate for years to come, shaping the future of digestive health worldwide.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.
    Authors: Yan J, Chen H, Zhang Y, Peng L, Wang Z, Lan X, Yu S, Yang Y.
    Year: 2024

 

  1. Title: Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Authors: Chen J, Zhang Y, Min H, Zhi J, Ma S, Dong H, Yan J, Chi X, Zhang X, Yang Y.
    Year: 2024

 

  1. Title: Colorectal cancer and gut microbiota studies in China.
    Authors: Wang Z, Dan W, Zhang N, Fang J, Yang Y.
    Year: 2023

 

  1. Title: The fecal microbiota from children with autism impact gut metabolism and learning and memory abilities of honeybees.
    Authors: Li Y, Zhang Y, Luo X, Meng Y, Zhong Z, Zheng H, Yang Y.
    Year: 2023

 

  1. Title: Deep insights into the gut microbial community of extreme longevity in South Chinese centenarians by ultra-deep metagenomics and large-scale culturomics.
    Authors: Li C, Luan Z, Zhao Y, Chen J, Yang Y, Wang C, Jing Y, Qi S, Li Z, Guo H, et al.
    Year: 2022